Lexeo Therapeutics is fostering innovation in cardiac gene therapy through its novel non-viral RNA delivery platform and collaboration with Abiomed leveraging the Impella heart pump for targeted gene delivery. While the company operates with significant operating losses and negative cash flows characteristic of clinical-stage biotech, it has fortified its balance sheet via multiple sizeable equity raises, enabling continued R&D investments. Key near-term milestones hinge on clinical progress and regulatory outcomes amid a competitive landscape and ongoing legal risk resolution.